REN001 ( DrugBank: ReN001 )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 256 | Muscle glycogenosis | 1 |
256. Muscle glycogenosis
Clinical trials : 180 / Drugs : 133 - (DrugBank : 29) / Drug target genes : 25 - Drug target pathways : 105
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | NCT04226274 (ClinicalTrials.gov) | December 10, 2019 | 9/1/2020 | A Study of the Safety of REN001 in Patients With McArdle Disease | A Phase 1b, Open-label Study to Evaluate the Safety and Tolerability of 12 Weeks Treatment With Oral REN001 in Patients With McArdle Disease (Glycogen Storage Disorder 5) | McArdle Disease | Drug: REN001 | Reneo Pharma Ltd | NULL | Completed | 18 Years | N/A | All | 19 | Phase 1 | Spain;United Kingdom |